Advertisement

Current Sexual Health Reports

, Volume 11, Issue 3, pp 190–200 | Cite as

Minimizing Sexual Dysfunction in BPH Surgery

  • Joon Yau LeongEmail author
  • Amir S. Patel
  • Ranjith Ramasamy
Male and Female Surgical Interventions (C Carson and M Khera, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Male and Female Surgical Interventions

Abstract

Purpose of Review

To review the prevalence and risks of sexual dysfunction associated with current treatment options for benign prostatic hyperplasia and to characterize techniques and methods to manage postoperative sexual dysfunction-related side effects.

Recent Findings

Current surgical therapies available for the treatment of benign prostatic hyperplasia are associated with a substantial risk of both ejaculatory and erectile function. However, many of the novel minimally invasive treatment alternatives have demonstrated the ability to preserve postoperative sexual function to a better degree, all while providing significant relief of lower urinary tract symptoms in an equally safe and efficacious manner.

Summary

Benign prostatic hyperplasia remains a highly prevalent disease among the aging population. While surgical treatments are often necessary to relieve bothersome urinary symptoms, these procedures are associated with an increased risk of sexual dysfunction. As such, there has been an increased interest in the development of minimally invasive therapies, such as the UroLift®, Rezum®, and Aquablation®, with the hopes of achieving similar symptomatic relief while maintaining sexual function. Aside from reporting lower rates of sexual dysfunction, these procedures have also demonstrated comparable safety, durability, and efficacy to current gold standard therapies. Some procedures can even be performed in an outpatient setting, avoiding the need for general anesthesia altogether. Overall, an individualized, shared decision-making approach is necessary to determine the ideal treatment option for each patient.

Keywords

Benign prostatic hyperplasia Lower urinary tract symptoms Sexual dysfunction Erectile dysfunction Ejaculatory dysfunction 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7(Suppl 9):S3–S14.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Borchert A, Leavitt DA. A review of male sexual health and dysfunction following surgical treatment for benign prostatic hyperplasia and lower urinary tract symptoms. Curr Urol Rep. 2018;19(8):66.  https://doi.org/10.1007/s11934-018-0813-0. This comprehensive review summarizes post-procedural sexual dysfunction after utility of current treatment modalities available for BPH. CrossRefPubMedGoogle Scholar
  4. 4.
    Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol. 1997;31(3):272–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Alloussi SH, Lang C, Eichel R, Alloussi S. Ejaculation-preserving transurethral resection of prostate and bladder neck: short- and long-term results of a new innovative resection technique. J Endourol. 2014;28(1):84–9.  https://doi.org/10.1089/end.2013.0093.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim M, Song SH, Ku JH, Kim HJ, Paick JS. Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate. Int J Impot Res. 2015;27(1):20–4.  https://doi.org/10.1038/ijir.2014.22.CrossRefPubMedGoogle Scholar
  7. 7.
    Talab SS, Santiago-Lastra YA, Bachmann A, Choi BB, Muir GH, Woo HH, et al. V403 the impact of ejaculation-preserving photo-selective vaporization of the prostate (EP-PVP) on lower urinary tract symptoms and ejaculatory function: results of a multicenter study. J Urol. 2013;189(4S):e164.  https://doi.org/10.1016/j.juro.2013.02.1792.CrossRefGoogle Scholar
  8. 8.
    Wang P, Xia D, Ye S, Kong D, Qin J, Jing T, et al. Robotic-assisted urethra-sparing simple prostatectomy via an extraperitoneal approach. Urology. 2018;119:85–90.  https://doi.org/10.1016/j.urology.2018.06.005.CrossRefPubMedGoogle Scholar
  9. 9.
    •• Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802–13. This prospective, randomized controlled trial is the landmark study evaluating the efficacy of UroLift of up to 5 years. PubMedGoogle Scholar
  10. 10.
    McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Urology. 2018;111:1–9.  https://doi.org/10.1016/j.urology.2017.10.023.CrossRefPubMedGoogle Scholar
  11. 11.
    Kasivisvanathan V, Hussain M. Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes. Can J Urol. 2018;25(3):9317–22.PubMedGoogle Scholar
  12. 12.
    Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115–22.  https://doi.org/10.1016/j.jvir.2016.04.001.CrossRefPubMedGoogle Scholar
  13. 13.
    Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol. 2013;189(4):1421–6.  https://doi.org/10.1016/j.juro.2012.11.003.CrossRefPubMedGoogle Scholar
  14. 14.
    Porpiglia F, Fiori C, Bertolo R, Giordano A, Checcucci E, Garrou D, et al. 3-year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int. 2018;122(1):106–12.  https://doi.org/10.1111/bju.14141.CrossRefPubMedGoogle Scholar
  15. 15.
    Fan Y-H, Lin A, Huang E, Chen K-K. Health care-seeking behavior in benign prostatic hyperplasia patients. Urol Sci. 2017;28(3):169–73.CrossRefGoogle Scholar
  16. 16.
    Catania JA, Oakley LP, Rosen R, Pollack LM. Effects of interview mode on assessments of erectile and ejaculatory dysfunction among men with benign prostatic hyperplasia (BPH). J Sex Res. 2013;50(6):524–36.  https://doi.org/10.1080/00224499.2012.666815.CrossRefPubMedGoogle Scholar
  17. 17.
    Cornell LF, Mussallem DM, Gibson TC, Diehl NN, Bagaria SP, McLaughlin SA. Trends in sexual function after breast cancer surgery. Ann Surg Oncol. 2017;24(9):2526–38.  https://doi.org/10.1245/s10434-017-5894-3.CrossRefPubMedGoogle Scholar
  18. 18.
    Gil-Vernet JM, Alvarez-Vijande R, Gil-Vernet A. Ejaculation in men: a dynamic endorectal ultrasonographical study. Br J Urol. 1994;73(4):442–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Bruyère F. The relationship between photoselective vaporization of the prostate and sexual function. Curr Urol Rep. 2011;12(4):261–4.  https://doi.org/10.1007/s11934-011-0199-8.CrossRefPubMedGoogle Scholar
  20. 20.
    Pavone C, Abbadessa D, Scaduto G, Caruana G, Scalici Gesolfo C, Fontana D, et al. Sexual dysfunctions after transurethral resection of the prostate (TURP): evidence from a retrospective study on 264 patients. Arch Ital Urol Androl. 2015;87(1):8–13.  https://doi.org/10.4081/aiua.2015.1.8.CrossRefPubMedGoogle Scholar
  21. 21.
    Muntener M, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebel RT. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol. 2007;52(2):510–5.  https://doi.org/10.1016/j.eururo.2007.01.088.CrossRefPubMedGoogle Scholar
  22. 22.
    Chung A, Woo HH. Preservation of sexual function when relieving benign prostatic obstruction surgically: can a trade-off be considered? Curr Opin Urol. 2016;26(1):42–8.  https://doi.org/10.1097/MOU.0000000000000247.CrossRefPubMedGoogle Scholar
  23. 23.
    Becher EF, McVary KT. Surgical procedures for BPH/LUTS: impact on male sexual health. Sex Med Rev. 2014;2(1):47–55.  https://doi.org/10.1002/smrj.20.CrossRefPubMedGoogle Scholar
  24. 24.
    Bruyère F, Puichaud A, Pereira H, Faivre d'Arcier B, Rouanet A, Floc'h AP, et al. Influence of photoselective vaporization of the prostate on sexual function: results of a prospective analysis of 149 patients with long-term follow-up. Eur Urol. 2010;58(2):207–11.  https://doi.org/10.1016/j.eururo.2010.04.027.CrossRefPubMedGoogle Scholar
  25. 25.
    Coursey JW, Morey AF, McAninch JW, Summerton DJ, Secrest C, White P, et al. Erectile function after anterior urethroplasty. J Urol. 2001;166(6):2273–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;200(3):612–9.  https://doi.org/10.1016/j.juro.2018.05.048.CrossRefPubMedGoogle Scholar
  27. 27.
    Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. 1989. J Urol. 2002;167(2 Pt 2):999–1003 discussion 4.CrossRefPubMedGoogle Scholar
  28. 28.
    • Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P. Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men's ejaculatory function: time for a bespoke approach? Int J Urol. 2016;23(1):22–35.  https://doi.org/10.1111/iju.12866. This review examines the effect of current surgical therapies and minimally invasive procedures for BPH on ejaculatory function. CrossRefPubMedGoogle Scholar
  29. 29.
    Donovan JL, Peters TJ, Neal DE, Brookes ST, Gujral S, Chacko KN, et al. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: the CLasP study. J Urol. 2000;164(1):65–70.CrossRefPubMedGoogle Scholar
  30. 30.
    Taher A. Erectile dysfunction after transurethral resection of the prostate: incidence and risk factors. World J Urol. 2004;22(6):457–60.  https://doi.org/10.1007/s00345-004-0449-1.CrossRefPubMedGoogle Scholar
  31. 31.
    Møller-Nielsen C, Lundhus E, Møller-Madsen B, Nørgaard JP, Simonsen OH, Hansen SL, et al. Sexual life following ‘minimal’ and ‘total’ transurethral prostatic resection. Urol Int. 1985;40(1):3–4.  https://doi.org/10.1159/000281022.CrossRefPubMedGoogle Scholar
  32. 32.
    Mamoulakis C, Skolarikos A, Schulze M, Scoffone CM, Rassweiler JJ, Alivizatos G, et al. Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. BJU Int. 2013;112(1):109–20.  https://doi.org/10.1111/j.1464-410X.2012.11662.x.CrossRefPubMedGoogle Scholar
  33. 33.
    Chen Q, Zhang L, Fan QL, Zhou J, Peng YB, Wang Z. Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up. BJU Int. 2010;106(9):1339–43.  https://doi.org/10.1111/j.1464-410X.2010.09401.x.CrossRefPubMedGoogle Scholar
  34. 34.
    El-Assmy A, ElShal AM, Mekkawy R, El-Kappany H, Ibrahiem EHI. Erectile and ejaculatory functions changes following bipolar versus monopolar transurethral resection of the prostate: a prospective randomized study. Int Urol Nephrol. 2018;50(9):1569–76.  https://doi.org/10.1007/s11255-018-1950-6.CrossRefPubMedGoogle Scholar
  35. 35.
    • Frieben RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE, Wang R. The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. Asian J Androl. 2010;12(4):500–8.  https://doi.org/10.1038/aja.2010.33 This systematic review of randomized controlled trials and cohort studies report the impact of male sexual function of minimally invasive surgeries when compared to TURP. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Keehn A, Fram E, Garg M, Maria P. UroLift in place of fiducial markers for patients with benign prostatic hyperplasia undergoing external beam radiation therapy. Urology. 2017;104:230–4.  https://doi.org/10.1016/j.urology.2016.11.029.CrossRefPubMedGoogle Scholar
  37. 37.
    Mock S, Leapman M, Stock RG, Hall SJ, Stone NN. Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters. J Urol. 2013;190(5):1805–10.  https://doi.org/10.1016/j.juro.2013.05.010.CrossRefPubMedGoogle Scholar
  38. 38.
    Gilling PJ, Kennett K, Das AK, Thompson D, Fraundorfer MR. Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. J Endourol. 1998;12(5):457–9.  https://doi.org/10.1089/end.1998.12.457.CrossRefPubMedGoogle Scholar
  39. 39.
    Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol. 2008;53(1):160–6.  https://doi.org/10.1016/j.eururo.2007.08.036.CrossRefPubMedGoogle Scholar
  40. 40.
    Meng F, Gao B, Fu Q, Chen J, Liu Y, Shi B, et al. Change of sexual function in patients before and after Ho:YAG laser enucleation of the prostate. J Androl. 2007;28(2):259–61.  https://doi.org/10.2164/jandrol.106.000372.CrossRefPubMedGoogle Scholar
  41. 41.
    Briganti A, Naspro R, Gallina A, Salonia A, Vavassori I, Hurle R, et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. J Urol. 2006;175(5):1817–21.  https://doi.org/10.1016/S0022-5347(05)00983-3.CrossRefPubMedGoogle Scholar
  42. 42.
    Zong HT, Peng XX, Yang CC, Zhang Y. The impact of transurethral procedures for benign prostate hyperplasia on male sexual function: a meta-analysis. J Androl. 2012;33(3):427–34.  https://doi.org/10.2164/jandrol.111.013490.CrossRefPubMedGoogle Scholar
  43. 43.
    • DeLay KJ, Nutt M, McVary KT. Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. Transl Androl Urol. 2016;5(4):450–9.  https://doi.org/10.21037/tau.2016.06.06. This review examines the effect of current surgical therapies and minimally invasive procedures for BPH on ejaculatory function. CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Bachmann A, Tubaro A, Barber N, d’Ancona F, Muir G, Witzsch U, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial--the GOLIATH study. Eur Urol. 2014;65(5):931–42.  https://doi.org/10.1016/j.eururo.2013.10.040.CrossRefPubMedGoogle Scholar
  45. 45.
    Thomas JA, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, et al. A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study. Eur Urol. 2016;69(1):94–102.  https://doi.org/10.1016/j.eururo.2015.07.054.CrossRefPubMedGoogle Scholar
  46. 46.
    Spaliviero M, Strom KH, Gu X, Araki M, Culkin DJ, Wong C. Does Greenlight HPS(™) laser photoselective vaporization prostatectomy affect sexual function? J Endourol. 2010;24(12):2051–7.  https://doi.org/10.1089/end.2010.0296.CrossRefPubMedGoogle Scholar
  47. 47.
    Elshal AM, Elmansy HM, Elkoushy MA, Elhilali MM. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. Urology. 2012;80(5):1098–104.  https://doi.org/10.1016/j.urology.2012.08.001.CrossRefPubMedGoogle Scholar
  48. 48.
    Kavoussi PK, Hermans MR. Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hyperplasia. J Sex Med. 2008;5(11):2669–71.  https://doi.org/10.1111/j.1743-6109.2008.00978.x.CrossRefPubMedGoogle Scholar
  49. 49.
    Li Z, Chen P, Wang J, Mao Q, Xiang H, Wang X, et al. The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: a systematic review and network meta-analysis. Medicine (Baltimore). 2016;95(24):e3862.  https://doi.org/10.1097/MD.0000000000003862.CrossRefGoogle Scholar
  50. 50.
    Ponholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. Int J Impot Res. 2007;19(6):544–50.  https://doi.org/10.1038/sj.ijir.3901578.CrossRefPubMedGoogle Scholar
  51. 51.
    Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 1998;159(5):1588–93; discussion 93-4.  https://doi.org/10.1097/00005392-199805000-00048.CrossRefPubMedGoogle Scholar
  52. 52.
    Ahmed M, Bell T, Lawrence WT, Ward JP, Watson GM. Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. Br J Urol. 1997;79(2):181–5.CrossRefPubMedGoogle Scholar
  53. 53.
    Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol. 2003;17(2):103–7.  https://doi.org/10.1089/08927790360587432.CrossRefPubMedGoogle Scholar
  54. 54.
    Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004;171(6 Pt 1):2336–40.CrossRefPubMedGoogle Scholar
  55. 55.
    • Herberts M, Butcher M, Köhler T. The effect of LUTS/BPH and treatments on ejaculatory function. Curr Urol Rep. 2016;17(7):48.  https://doi.org/10.1007/s11934-016-0604-4. This review examines the effect of current surgical therapies and minimally invasive procedures for BPH on ejaculatory function. CrossRefPubMedGoogle Scholar
  56. 56.
    Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, et al. Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. BJU Int. 2014;113(4):615–22.  https://doi.org/10.1111/bju.12540.CrossRefPubMedGoogle Scholar
  57. 57.
    Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2012;79(1):5–11.  https://doi.org/10.1016/j.urology.2011.10.021.CrossRefPubMedGoogle Scholar
  58. 58.
    Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012;9(2):568–75.  https://doi.org/10.1111/j.1743-6109.2011.02568.x.CrossRefPubMedGoogle Scholar
  59. 59.
    Shore N, Freedman S, Gange S, Moseley W, Heron S, Tutrone R, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. Can J Urol. 2014;21(1):7094–101.PubMedGoogle Scholar
  60. 60.
    Roehrborn CG. Prostatic urethral lift: a unique minimally invasive surgical treatment of male lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urol Clin North Am. 2016;43(3):357–69.  https://doi.org/10.1016/j.ucl.2016.04.008.CrossRefPubMedGoogle Scholar
  61. 61.
    Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F.T. study. Can J Urol. 2015;22(3):7772–82.PubMedGoogle Scholar
  62. 62.
    Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. study. J Urol. 2013;190(6):2161–7.  https://doi.org/10.1016/j.juro.2013.05.116.CrossRefPubMedGoogle Scholar
  63. 63.
    McVary KT, Gange SN, Shore ND, Bolton DM, Cowan BE, Brown BT, et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med. 2014;11(1):279–87.  https://doi.org/10.1111/jsm.12333.CrossRefPubMedGoogle Scholar
  64. 64.
    Sønksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. Eur Urol. 2015;68(4):643–52.  https://doi.org/10.1016/j.eururo.2015.04.024.CrossRefPubMedGoogle Scholar
  65. 65.
    Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezūm system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Res Rep Urol. 2017;9:159–68.  https://doi.org/10.2147/RRU.S143679.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezūm system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042–7.  https://doi.org/10.1016/j.urology.2015.05.046.CrossRefPubMedGoogle Scholar
  67. 67.
    •• McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019.  https://doi.org/10.1016/j.urology.2018.12.041. This prospective, randomized controlled study is the landmark study evaluating the efficacy of Rezum of up to 4 years.
  68. 68.
    McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–38.  https://doi.org/10.1016/j.juro.2015.10.181.CrossRefPubMedGoogle Scholar
  69. 69.
    McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. J Sex Med. 2016;13(6):924–33.  https://doi.org/10.1016/j.jsxm.2016.03.372.CrossRefPubMedGoogle Scholar
  70. 70.
    Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–16.  https://doi.org/10.2147/RRU.S119596.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Mollengarden D, Goldberg K, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. Prostate Cancer Prostatic Dis. 2018;21(3):379–85.  https://doi.org/10.1038/s41391-017-0022-9.CrossRefPubMedGoogle Scholar
  72. 72.
    Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. J Urol. 2017;197(6):1507–16.  https://doi.org/10.1016/j.juro.2016.12.045.CrossRefPubMedGoogle Scholar
  73. 73.
    MacRae C, Gilling P. How I do it: aquablation of the prostate using the AQUABEAM system. Can J Urol. 2016;23(6):8590–3.PubMedGoogle Scholar
  74. 74.
    Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int. 2016;117(6):923–9.  https://doi.org/10.1111/bju.13358.CrossRefPubMedGoogle Scholar
  75. 75.
    • Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol. 2017;197(6):1565–72.  https://doi.org/10.1016/j.juro.2017.01.056 This prospective single arm study aimed to assess the safety and efficacy of aquablation. CrossRefPubMedGoogle Scholar
  76. 76.
    Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of aquablation. J Urol. 2018;199(5):1252–61.  https://doi.org/10.1016/j.juro.2017.12.065.CrossRefPubMedGoogle Scholar
  77. 77.
    • Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Randomized controlled trial of aquablation versus transurethral resection of the prostate in benign prostatic hyperplasia: one-year outcomes. Urology. 2019;125:169–73.  https://doi.org/10.1016/j.urology.2018.12.002. This study reports the most recent 1 year outcomes comparing the safety and efficacy of aquablation to TURP. CrossRefPubMedGoogle Scholar
  78. 78.
    Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, Morgia G, et al. Prostatic artery embolization for prostate volume greater than 80 cm3: results from a single-center prospective study. Urology. 2014;84(2):400–4.  https://doi.org/10.1016/j.urology.2014.04.028.CrossRefPubMedGoogle Scholar
  79. 79.
    Li Q, Duan F, Wang MQ, Zhang GD, Yuan K. Prostatic arterial embolization with small sized particles for the treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia: preliminary results. Chin Med J. 2015;128(15):2072–7.  https://doi.org/10.4103/0366-6999.161370.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Wang MQ, Guo LP, Zhang GD, Yuan K, Li K, Duan F, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. BMC Urol. 2015;15:33.  https://doi.org/10.1186/s12894-015-0026-5.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Isaacson AJ, Raynor MC, Yu H, Burke CT. Prostatic artery embolization using embosphere microspheres for prostates measuring 80-150 cm(3): early results from a US trial. J Vasc Interv Radiol. 2016;27(5):709–14.  https://doi.org/10.1016/j.jvir.2016.01.146.CrossRefPubMedGoogle Scholar
  82. 82.
    Bagla S, Smirniotopoulos JB, Orlando JC, van Breda A, Vadlamudi V. Comparative analysis of prostate volume as a predictor of outcome in prostate artery embolization. J Vasc Interv Radiol. 2015;26(12):1832–8.  https://doi.org/10.1016/j.jvir.2015.08.018.CrossRefPubMedGoogle Scholar
  83. 83.
    Wang M, Guo L, Duan F, Yuan K, Zhang G, Li K, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms as a result of large benign prostatic hyperplasia: a prospective single-center investigation. Int J Urol. 2015;22(8):766–72.  https://doi.org/10.1111/iju.12797.CrossRefPubMedGoogle Scholar
  84. 84.
    Pisco J, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Prostate embolization as an alternative to open surgery in patients with large prostate and moderate to severe lower urinary tract symptoms. J Vasc Interv Radiol. 2016;27(5):700–8.  https://doi.org/10.1016/j.jvir.2016.01.138.CrossRefPubMedGoogle Scholar
  85. 85.
    Wang M, Guo L, Duan F, Yuan K, Zhang G, Li K, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates. BJU Int. 2016;117(1):155–64.  https://doi.org/10.1111/bju.13147.CrossRefPubMedGoogle Scholar
  86. 86.
    Wang XY, Zong HT, Zhang Y. Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis. Clin Interv Aging. 2016;11:1609–22.  https://doi.org/10.2147/CIA.S119241.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. 2018;122(2):270–82.  https://doi.org/10.1111/bju.14249.CrossRefPubMedGoogle Scholar
  88. 88.
    Pham H, Sharma P. Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. Can J Urol. 2018;25(2):9228–37.PubMedGoogle Scholar
  89. 89.
    Bowen DK, Butcher MJ, Botchway A, McVary KT. Counseling on sexual side effects from TURP. Can J Urol. 2015;22(6):8063–8.PubMedGoogle Scholar
  90. 90.
    Albaugh JA, Sufrin N, Lapin BR, Petkewicz J, Tenfelde S. Life after prostate cancer treatment: a mixed methods study of the experiences of men with sexual dysfunction and their partners. BMC Urol. 2017;17(1):45.  https://doi.org/10.1186/s12894-017-0231-5.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Patel RM, Bariol S. National trends in surgical therapy for benign prostatic hyperplasia in Australia. ANZ J Surg. 2019;89(4):345–9.  https://doi.org/10.1111/ans.15016.CrossRefPubMedGoogle Scholar
  92. 92.
    Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008). Urology. 2012;79(5):1111–6.  https://doi.org/10.1016/j.urology.2011.11.084.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Joon Yau Leong
    • 1
    Email author
  • Amir S. Patel
    • 2
  • Ranjith Ramasamy
    • 3
  1. 1.Department of UrologySidney Kimmel Medical College, Thomas Jefferson UniversityPhiladelphiaUSA
  2. 2.Department of UrologyOregon Health and Science UniversityPortlandUSA
  3. 3.Department of UrologyUniversity of Miami Miller School of MedicineMiamiUSA

Personalised recommendations